Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan

ConclusionsDuring the mandatory postmarketing survey of Ziagen, there were no cases of ischemic heart diseases, and the incidence of hypersensitivity was considerably low. These indicated that abacavir can be safely used in Japanese HIV+ population. However, the safety profile of Ziagen should be continued to be monitored through pharmacovigilance. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.

Source: Pharmacoepidemiology and Drug Safety - February 1, 2014 Category: Drugs & Pharmacology Authors: Tomoko Kurita, Tomomi Kitaichi, Takako Nagao, Toshiyuki Miura, Yoshifumi Kitazono Tags: Original Report Source Type: research